The main functions and clinical indications of rubicatin/rubitin

Lurbinectedin is an innovative anti-tumor drug with a unique mechanism of action. It mainly inhibits RNA polymerase II activity and blocks transcriptional activities in cancer cells, thereby inducing tumor cell apoptosis and controlling tumor spread. Its clinical value is particularly outstanding in metastatic small cell lung cancer (SCLC). This type of tumor grows rapidly, metastasizes early and is highly resistant to traditional chemotherapy. It is currently one of the most difficult subtypes of lung cancer to treat.

Rubitin has received accelerated approval for recurrent SCLC in many countries and has been included in the treatment standard. Its indications are mainly concentrated in patients who have relapsed after treatment with platinum drugs, especially in patients with platinum sensitivity (relapse time exceeds 90 days). In addition, the drug has also been explored for the treatment of other malignant tumors, such as ovarian cancer, breast cancer, and malignant mesothelioma. Preliminary data shows that it may also have therapeutic potential in some refractory solid tumors. Although rubitidine has been officially approved for marketing in China, it has not yet been included in medical insurance, and its main indications are still small cell lung cancer. Its unique molecular mechanism gives it a toxic and side effect profile that is different from traditional chemotherapy drugs. Its most common adverse reactions include neutropenia, fatigue and nausea.

Overall, rubitin provides a new chemotherapy alternative for advanced small cell lung cancer. It is an important treatment option to extend survival for patients who have failed or relapsed with traditional treatments. Its efficacy has been positively recognized in global multi-center trials. As more research data accumulates, rubitidine is expected to expand its indications and become an important treatment for a variety of refractory tumors.

Reference materials:https://www.zepzelca.com/